Vabysmo 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
II/0002 
Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC 
22/06/2023 
SmPC and PL 
The SmPC has been updated in line with the safety and 
in order to update efficacy and safety information 
and to update the warnings and the list of adverse 
drug reactions (ADRs), based on longer-term results 
from studies GR40306 (TENAYA) and GR40844 
(LUCERNE); these are phase 3, multicenter, 
efficacy data from long-term studies. The posology for 
neovascular age related macular degeneration, adverse 
events frequency and section 5.1 are updated in line with 
the long-term treatment study findings. The proposed 
changes can be agreed if there are satisfactory responses 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
to the list of issues and supplementary information 
requested. 
randomized, double-masked, active comparator-
controlled, 112-week studies to evaluate the efficacy 
and safety of faricimab in patients with neovascular 
age-related macular degeneration (nAMD); the 
Package Leaflet is updated accordingly. The RMP 
version 2.0 has also been submitted. In addition, the 
MAH took the opportunity to introduce minor 
editorial changes to the PI. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0003 
B.I.b.z - Change in control of the AS - Other 
04/04/2023 
n/a 
variation 
IB/0001 
B.I.a.2.a - Changes in the manufacturing process of 
09/11/2022 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
